Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 6/20 | 0.35 |
| ▸ | PPARD | Q03181 | 6/20 | 0.35 |
| ▸ | PPARA | Q07869 | 6/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149679 | 0.95 | LMNA (0.53) | LMNAMEN1KMT2AMAPTATM | |
| SCHEMBL21802732 | 0.87 | LMNA (0.47) | LMNAMEN1KMT2AMAPTATM | |
| SCHEMBL2498627 | 0.85 | LMNA (0.49) | LMNAMEN1KMT2AMAPTPPARG | |
| SCHEMBL11589631 | 0.84 | LMNA (0.47) | LMNAMEN1KMT2AMAPTPPARG | |
| SCHEMBL381316 | 0.80 | LMNA (0.46) | LMNAMEN1KMT2AMAPTATM | |
| SCHEMBL4653090 | 0.79 | MAPT (0.42) | LMNAMEN1KMT2AMAPTATM | |
| Acetic Acid SCHEMBL8601641 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL20747697 | 0.79 | LMNA (0.52) | LMNAMEN1KMT2AMAPTATM | |
| Acetic Acid SCHEMBL1925892 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL20747681 | 0.79 | LMNA (0.52) | LMNAMEN1KMT2AMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110198949-B | Process for the preparation of 9 beta, 10 alpha-progesterone (retroprogesterone) | 工业化学有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-10654885-B2 | Process for the preparation of 9 beta,10 alpha-progesterone (retroprogesterone) | INDUSTRIALE CHIMCA S.R.L. (IT) | 2020-05-19 | — | — | US | disclosed |
| US-20200040029-A1 | PROCESS FOR THE PREPARATION OF 9 BETA,10 ALPHA-PROGESTERONE (RETROPROGESTERONE) | INDUSTRIALE CHIMCA S.R.L. (IT) | 2020-02-06 | — | — | US | disclosed |
| US-6706727-B1 | ethyl-4-chloro- or 4-hydroxy- Ascomycin derivatives; pimecrolimus homologues; cultivating Streptomyces hygroscopius to produce the 4-hydroxy derivative; replacement of the hydroxy with chloro under epimerization; antiinflammatory; immunosupression | NOVARTIS AG (CH) | 2004-03-16 | — | — | US | disclosed |
| EP-1289997-B1 | MACROLIDES | NOVARTIS AG (CH) | 2004-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654885-B2 | Process for the preparation of 9 beta,10 alpha-progesterone (retroprogesterone) | CYP17A1, HSD17B11, CYP19A1 | ESR1 46/4885LMNA 1762/4885MEN1 2096/4885 |
| US-20200040029-A1 | PROCESS FOR THE PREPARATION OF 9 BETA,10 ALPHA-PROGESTERONE (RETROPROGESTERONE) | CYP17A1, HSD17B11, CYP19A1 | ESR1 46/4885LMNA 1762/4885MEN1 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.